TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31111409

Group type: EXPERIMENTAL
Intervention: Glycopyrronium tosylate (2.4%) applied once daily
Number of subjects: 550
Study: 30541586

Group type: EXPERIMENTAL
Intervention: Real electroacupuncture (EA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham electroacupuncture (placebo)
Number of subjects: 100
Study: 26914224

Group type: EXPERIMENTAL
Intervention: Etomidate 0.15 mg/kg
Number of subjects: 130

Group type: COMPARATOR
Intervention: Propofol 1.5 mg/kg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Etomidate 0.15 mg/kg with hydrocortisone
Number of subjects: 130
Study: 23661634

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 36

Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 22249601

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound with perflutren contrast agent
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Postcontrast ultrasound
Number of subjects: 13
Study: 19346662

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 241

Group type: COMPARATOR
Intervention: ACEI
Number of subjects: 241
Study: 17595007

Group type: EXPERIMENTAL
Intervention: Rumination (writing about the aggressive video for 20 min) combined with minor frustration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Minor frustration
Number of subjects: 60

Group type: COMPARATOR
Intervention: No rumination (irrelevant task for 20 min)
Number of subjects: 60
Study: 15196302

Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg intravenous LY293558
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 6 mg subcutaneous sumatriptan
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 14578014

Group type: EXPERIMENTAL
Intervention: Flumazenil (FLU) 1 mg twice a day for 8 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oxazepam tapering (from 120 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Flumazenil (FLU)
Number of subjects: 50
Study: 9835002

Group type: EXPERIMENTAL
Intervention: Pneumatic compression device
Number of subjects: 1017

Group type: COMPARATOR
Intervention: Clamp compression technique
Number of subjects: 1017
Study: 9892226

Group type: EXPERIMENTAL
Intervention: Exendin 9-39 (500 pmol x kg(-1) x min(-1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study: 2499464

Group type: EXPERIMENTAL
Intervention: Adenosine (bolus doses of 5.3 to 15.9 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Theophylline (58.3 +/- 3.3 mumol l‐1 plasma)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipyridamole (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol, Atropine, Naloxone, Cromolyn Sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyperventilation
Number of subjects: 0
Study: 842760

Group type: EXPERIMENTAL
Intervention: High protein‐calorie supplementation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin and mineral supplement with one‐third of the calories
Number of subjects: 0
Study: 30926369

Group type: EXPERIMENTAL
Intervention: M1095 (240 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: M1095 (30, 60, 120, or 240 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: M1095
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 27845200

Group type: COMPARATOR
Intervention: High-dose KME (2g/d)
Number of subjects: 67

Group type: COMPARATOR
Intervention: KME groups (low-dose and high-dose)
Number of subjects: 67
Study: 26870788

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Linezolid 300 mg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Linezolid (both doses)
Number of subjects: 38
Study: 23446898

Group type: EXPERIMENTAL
Intervention: 50% price discounts on F&Vs
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: 50% price discounts plus nutrition education
Number of subjects: 199

Group type: COMPARATOR
Intervention: Nutrition education alone
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 199
Study: 22273030

Group type: EXPERIMENTAL
Intervention: Qualitative assessment of experiences in the trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivations for participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fears associated with trial procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conducting qualitative research
Number of subjects: 0
Study: 19262457

Group type: EXPERIMENTAL
Intervention: Conventional hemofiltration (CUF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metilprednisolone (steroids)
Number of subjects: 24
Study: 16376296

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral workshop
Number of subjects: 85

Group type: COMPARATOR
Intervention: Assessment‐only waitlist group
Number of subjects: 85
Study: 15272899

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 0.75 mg/kg on alternate days, plus vitamin D 600-1200 units/day and a calcium-enriched diet
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 11283143

Group type: EXPERIMENTAL
Intervention: Ondansetron plus metopimazine
Number of subjects: 221

Group type: COMPARATOR
Intervention: Ondansetron plus metopimazine plus prednisolone
Number of subjects: 221
Study: 9242341

Group type: EXPERIMENTAL
Intervention: Interleukin-1 receptor antagonist (IL-1ra) 100 mg bolus followed by 2 mg/kg per hour intravenously for 72 hours (n = 20)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 37
Study: 8494702

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy including alkylating agents (n = 14)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oophorectomy (n = 12)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (n = 79)
Number of subjects: 26
Study: 3568065

Group type: EXPERIMENTAL
Intervention: Alclometasone dipropionate 0.05%
Number of subjects: 34

Group type: COMPARATOR
Intervention: Hydrocortisone 1.0%
Number of subjects: 34
Study: 31484697

Group type: EXPERIMENTAL
Intervention: Angioplasty/stenting
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Non-smokers
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Increasing lesion length
Number of subjects: 213

Group type: COMPARATOR
Intervention: FDA-approved indication for stenting
Number of subjects: 213
Study: 29724228

Group type: EXPERIMENTAL
Intervention: Tonic and Phasic Alertness Training (TAPAT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Active control training condition (computer games)
Number of subjects: 120
Study: 27099137

Group type: EXPERIMENTAL
Intervention: Morphine (5 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 11
Study: 24732867

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg (n=98)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg (n=70)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo (n=112)
Number of subjects: 280
Study: 22703550

Group type: EXPERIMENTAL
Intervention: Voluntary HIV counselling and testing (VCT)
Number of subjects: 6778

Group type: EXPERIMENTAL
Intervention: No stigmatizing attitudes toward people living with HIV/AIDS
Number of subjects: 6778

Group type: EXPERIMENTAL
Intervention: Younger men (aged ≤44 years) and those of higher socio-economic position (SEP) in rural areas
Number of subjects: 6778

Group type: EXPERIMENTAL
Intervention: Risky sexual behaviour among urban men
Number of subjects: 6778

Group type: EXPERIMENTAL
Intervention: Being Muslim
Number of subjects: 6778

Group type: EXPERIMENTAL
Intervention: Area of residence and socio-economic position (SEP)
Number of subjects: 6778
Study: 20042981

Group type: EXPERIMENTAL
Intervention: Participant reports on Economic indicators
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Participant reports on Community indicators
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Participant reports on Social indicators
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Participant reports on Satisfaction items
Number of subjects: 97

Group type: COMPARATOR
Intervention: Significant others' self-reported degree of awareness of participants' concerns
Number of subjects: 97

Group type: COMPARATOR
Intervention: Severity of TBI
Number of subjects: 97
Study: 18816381

Group type: EXPERIMENTAL
Intervention: Multidisciplinary fall prevention programme
Number of subjects: 166
Study: 15983288

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (0.8 mg/d)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study: 11999911

Group type: EXPERIMENTAL
Intervention: TRH test
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: DST
Number of subjects: 58
Study: 10372975

Group type: EXPERIMENTAL
Intervention: Isotonic saline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (850 mmol L(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Time control (no saline infusion)
Number of subjects: 8
Study: 8826919

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening mammography (excluding Canadian National Breast Screening Study results)
Number of subjects: 0
Study: 2350441

Group type: EXPERIMENTAL
Intervention: Zidovudine with a high-fat meal
Number of subjects: 8

Group type: COMPARATOR
Intervention: Zidovudine without a high-fat meal
Number of subjects: 8
Study: 4539414

Group type: EXPERIMENTAL
Intervention: Cholera vaccine (1 dose)
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Cholera vaccine (2 doses)
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Cholera vaccine (3 doses)
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Cholera vaccine (4 doses)
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Cholera vaccine (1 dose annually for 3 years)
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Cholera vaccine (2 doses in the first year followed by annual reimmunizations)
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Cholera vaccine (after 4 doses)
Number of subjects: 40000
Study: 31039753

Group type: EXPERIMENTAL
Intervention: Multi-component pregnancy lifestyle intervention (adapted from the Diabetes Prevention Program)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 400
Study: 28699559

Group type: EXPERIMENTAL
Intervention: Covering water containers
Number of subjects: 11995

Group type: EXPERIMENTAL
Intervention: Temephos application in water containers
Number of subjects: 11995

Group type: EXPERIMENTAL
Intervention: Presence of temephos (in urban areas)
Number of subjects: 11995

Group type: COMPARATOR
Intervention: Having more than four water containers
Number of subjects: 11995

Group type: COMPARATOR
Intervention: Low education of the household head
Number of subjects: 11995

Group type: COMPARATOR
Intervention: Household head without paid work (in rural areas)
Number of subjects: 11995

Group type: COMPARATOR
Intervention: Being in the Acapulco region (in rural areas)
Number of subjects: 11995

Group type: COMPARATOR
Intervention: Using anti-mosquito products (in rural areas)
Number of subjects: 11995
Study: 25728846

Group type: COMPARATOR
Intervention: Placebo arm of the EVEREST trial
Number of subjects: 1907
Study: 24377216

Group type: EXPERIMENTAL
Intervention: Acupuncture group (shu‐stream point acupuncture combined with fire needle therapy)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medication group (votalin emulgel)
Number of subjects: 80
Study: 21490974

Group type: EXPERIMENTAL
Intervention: Psychoanalysts
Number of subjects: 14

Group type: COMPARATOR
Intervention: Medical students, oncologists, cognitive behavioral therapists, individuals with the same history of sibling's cancer
Number of subjects: 14
Study: 19371432

Group type: EXPERIMENTAL
Intervention: Warm-up
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Warm-up and static stretching
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Warm-up and static stretching response
Number of subjects: 36
Study: 16675058

Group type: EXPERIMENTAL
Intervention: Cycling retraining (GI)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Running retraining (GII)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (GIII)
Number of subjects: 47
Study: 15297895

Group type: EXPERIMENTAL
Intervention: Guided imagery relaxation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (rest quietly)
Number of subjects: 26
Study: 11738912

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (2 oral 500 mg doses at 12-hour intervals)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Levofloxacin (single oral 500 mg dose)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (single oral 400 mg dose)
Number of subjects: 42
Study: 8996152

Group type: EXPERIMENTAL
Intervention: Mitomycin as an adjunct to radiation therapy
Number of subjects: 203

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 203
Study: 8214177

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (8 sessions)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Social support group therapy (8 sessions)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 68
Study: 3677279

Group type: EXPERIMENTAL
Intervention: Sodium citrate (0.4 ml.kg‐1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 29073815

Group type: EXPERIMENTAL
Intervention: MeroGel (Group 1, n=72)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Cartilage (Group 2, n=64)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both MeroGel and cartilage (Group 3, n=69)
Number of subjects: 205
Study: 27716128

Group type: EXPERIMENTAL
Intervention: Tailored Treatment (TT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Non-Tailored Treatment (NTT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 120
Study: 24534128

Group type: EXPERIMENTAL
Intervention: Eptifibatide plus rt-PA (0.6 mg/kg rt-PA, 135 mcg/kg bolus, 0.75 mcg/kg/min two-hour infusion)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Eptifibatide plus rt-PA
Number of subjects: 54

Group type: COMPARATOR
Intervention: rt-PA alone (0.9 mg/kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: rt-PA alone
Number of subjects: 54
Study: 23740905

Group type: EXPERIMENTAL
Intervention: Case-based education course
Number of subjects: 0

Group type: COMPARATOR
Intervention: Facilitators' abilities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall impact of the course
Number of subjects: 0
Study: 20613484

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine (5, 10, 15, 20, 30, or 40 mg)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine (7, 15, 20, 30, 45, or 60 mg)
Number of subjects: 300
Study: 18756037

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (154 mmol/L intravenous infusion, bolus of 3 ml.kg(‐1).h(‐1) for 1 h before contrast, followed by infusion of 1 ml.kg(‐1).h(‐1) for 6 h during and after the procedure)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sodium chloride (154 mmol/L intravenous infusion, bolus of 3 ml.kg(‐1).h(‐1) for 1 h before contrast, followed by infusion of 1 ml.kg(‐1).h(‐1) for 6 h during and after the procedure)
Number of subjects: 59
Study: 16738029

Group type: EXPERIMENTAL
Intervention: High ranking competitors (e.g., #2 vs. #3)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low ranking competitors (e.g., #202 vs. #203)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Proximity to meaningful standards (e.g., bottom of a ranking scale or qualitative threshold)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Psychological processes related to proximity to a standard
Number of subjects: 8
Study: 15478158

Group type: EXPERIMENTAL
Intervention: Custom leather splint
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Rolyan commercial splint
Number of subjects: 45

Group type: COMPARATOR
Intervention: Anatech commercial splint
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All splints
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Wrist splints (overall)
Number of subjects: 45
Study: 11731729

Group type: EXPERIMENTAL
Intervention: labetalol 0.2 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: urapidil 25 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: no drug
Number of subjects: 27
Study: 9256187

Group type: EXPERIMENTAL
Intervention: T10B9
Number of subjects: 81

Group type: COMPARATOR
Intervention: OKT3
Number of subjects: 81

Group type: COMPARATOR
Intervention: Both mAbs
Number of subjects: 81
Study: 8098919

Group type: EXPERIMENTAL
Intervention: Tetanic stimulation (5 s, 50 Hz, 60 mA)
Number of subjects: 22
Study: 2956872

Group type: EXPERIMENTAL
Intervention: Enoximone (150 mg, 3 times daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg, 3 times daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (conventional therapy with diuretics)
Number of subjects: 13
Study: 31790144

Group type: COMPARATOR
Intervention: GnRH antagonist ganirelix
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ketoconazole (steroidogenic inhibitor)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High-dose ganirelix and repeated LH infusions
Number of subjects: 40
Study: 30500903

Group type: EXPERIMENTAL
Intervention: Lifestyle counselling (four times during pregnancy)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Control group (no lifestyle counselling)
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Lifestyle counselling
Number of subjects: 378

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 378
Study: 28129251

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 25585949

Group type: EXPERIMENTAL
Intervention: Urinary π-GST
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Lower urine Hepcidin:Creatine ratio at 24h
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Greater urine NGAL:Cr ratio post-op
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Greater serum CysC at 24h
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Hepcidin:Cr 24h + post-operative π-GST
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Hepcidin:Cr 24h + NGAL:Cr post-op
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CysC 24h + post-operative π-GST
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: NGAL:Cr measurement post-op followed by Hepcidin:Cr at 24h
Number of subjects: 93
Study: 23719397

Group type: EXPERIMENTAL
Intervention: Faces with lesions
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal faces
Number of subjects: 45
Study: 21350054

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 1817
Study: 19057210

Group type: EXPERIMENTAL
Intervention: PDE-5 inhibitors (sildenafil, vardenafil, tadalafil)
Number of subjects: 0
Study: 17407176

Group type: EXPERIMENTAL
Intervention: Rivastigmine patch
Number of subjects: 1059
Study: 15366391

Group type: EXPERIMENTAL
Intervention: Recycled stainless steel brackets
Number of subjects: 20

Group type: COMPARATOR
Intervention: New stainless steel brackets
Number of subjects: 20
Study: 11463545

Group type: EXPERIMENTAL
Intervention: HES 10% (200;0.5) colloid prime
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crystalloid prime (Ringer's lactate)
Number of subjects: 20
Study: 9663723

Group type: EXPERIMENTAL
Intervention: OCT (omeprazole 20 mg q.d.s. + clarithromycin 250 mg b.d. + tinidazole 500 mg b.d.)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: CT (clarithromycin 250 mg b.d. + tinidazole 500 mg b.d.)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: OC (omeprazole 20 mg o.d. + clarithromycin 250 mg b.d.)
Number of subjects: 128

Group type: COMPARATOR
Intervention: C (clarithromycin 250 mg b.d.)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: OCT (in patients with pre-treatment metronidazole resistance)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: CT (in patients with pre-treatment metronidazole resistance)
Number of subjects: 128

Group type: COMPARATOR
Intervention: C (post-treatment resistance to clarithromycin)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: OC (post-treatment resistance to clarithromycin)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: CT (post-treatment resistance to both antibiotics)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: OCT (post-treatment resistance to both antibiotics)
Number of subjects: 128
Study: 7933844

Group type: EXPERIMENTAL
Intervention: Constant infusion method
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Single injection technique
Number of subjects: 14

Group type: COMPARATOR
Intervention: Urinary clearance of inulin
Number of subjects: 14
Study: 3224003

Group type: EXPERIMENTAL
Intervention: Multiple Component Program
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Relapse Prevention Program
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: American Cancer Society Quitter's Guide
Number of subjects: 402

Group type: COMPARATOR
Intervention: Usual spontaneous quit rate
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Overall long-term quit rates
Number of subjects: 402
Study: 29642115

Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (MBSR)
Number of subjects: 34
Study: 27032074

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker
Number of subjects: 690

Group type: COMPARATOR
Intervention: No antihypertensive medication
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: All antihypertensive medications
Number of subjects: 690
Study: 24008787

Group type: EXPERIMENTAL
Intervention: Multimedia intervention (scripted verbal informed consent, 3-fold pamphlet, and 3D model presentation)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (scripted verbal informed consent only)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97